The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I-Ib trial of tivantinib in combination with carboplatin and pemetrexed as first-line treatment in patients (pts) with advanced nonsquamous NSCLC or malignant pleural mesothelioma (MPM).
Paolo A. Zucali
No relevant relationships to disclose
Matteo Simonelli
No relevant relationships to disclose
Fabio De Vincenzo
No relevant relationships to disclose
Giuseppe Fatuzzo
No relevant relationships to disclose
Monica Bertossi
No relevant relationships to disclose
Matteo B. Suter
No relevant relationships to disclose
Matteo Perrino
No relevant relationships to disclose
Laura Giordano
No relevant relationships to disclose
Armando Santoro
No relevant relationships to disclose